In this issue:
ProtecT: active monitoring of localised disease doesn’t increase mortality
Enzalutamide prolongs survival in mHSPC
TAPUR confirms role for PARP inhibitors in BRCA mutated disease
Does PSMA-PET/CT-guided biopsy have a role in primary staging?
No survival benefit to enzalutamide combo in mCRPC
Final survival data from PROpel
Early detection of prostate cancer: AUA/SUO Guideline
NALuPROST assesses neoadjuvant 177Lu-PSMA-I&T
Prostate cancer in transgender women
Use of active surveillance is increasing in the US
Rucaparib delays progression in BRCA mutated mCRPC
PBAC recommendations
PBS listings
COVID-19 resources
Conferences, Workshops & CPD
Please login below to download this issue (PDF)